

## Corrigendum

# Corrigendum to: PROTAC technology for prostate cancer treatment

Zhen Wang<sup>a,1</sup>, Dingpeng Zhang<sup>a,1</sup>, Hiroyuki Inuzuka<sup>a</sup> and Wenyi Wei<sup>a,\*</sup>

<sup>a</sup>Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

<sup>1</sup>These authors contribute equally.

\*Correspondence: [wwei2@bidmc.harvard.edu](mailto:wwei2@bidmc.harvard.edu) (W. Wei)

DOI 10.15212/AMM-2025-1005

In the publication by Wang et al., the authors have identified the following errors:

Reference "Laxman et al." was incorrectly cited in the first paragraph of Section 2.5 in the sentence "A study by Laxman et al. [75] first ... in the patients with PrCa." The citation "Laxman et al." should be corrected to "Tomlins et al." and reference [9] updated as follows:

Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, et al.: Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer. *Neoplasia* 2008, 10: 177–188.

The authors would like to update the following sentences due to the mismatch of author names with the corresponding references in the reference list:

In Section 5.3, second paragraph, 31st line, "Wang et al." should be corrected to "Han et al." in the sentence "In another significant development ... a highly potent AR degrader."

In Section 5.3, second paragraph, 33rd line, "Wang et al." should be corrected to "Han et al." in the

sentence "To address the poor oral bioavailability ... development of ARD-2128 (compound 6)."

Also, the authors would like to update reference [198] as follows:

Salami J, Alabi S, Willard RR, Vitale NJ, Wang J, Dong H, et al.: Androgen Receptor Degradation by the Proteolysis-Targeting Chimera ARCC-4 Outperforms Enzalutamide in Cellular Models of Prostate Cancer Drug Resistance. *Communications Biology* 2018, 1:1–9.

The authors regret that these errors were not identified during the final proof review and apologize for any inconvenience caused.

DOI of original article <https://doi.org/10.15212/AMM-2024-0075>

**Corrigendum to:** Zhen Wang, Dingpeng Zhang, Hiroyuki Inuzuka, Wenyi Wei. 2025. PROTAC technology for prostate cancer treatment. *Acta Materia Medica*. Volume 4, Issue 1, pages 99–121. (DOI: [10.15212/AMM-2024-0075](https://doi.org/10.15212/AMM-2024-0075))